Clinical Laserthermia Systems Management

Management criteria checks 4/4

Clinical Laserthermia Systems' CEO is Dan Mogren, appointed in Dec 2020, has a tenure of 3.33 years. total yearly compensation is SEK1.37M, comprised of 74.3% salary and 25.7% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth €198.40K. The average tenure of the management team and the board of directors is 2.3 years and 3.3 years respectively.

Key information

Dan Mogren

Chief executive officer

kr1.4m

Total compensation

CEO salary percentage	74.3%
CEO tenure	3.3yrs
CEO ownership	0.008%
Management average tenure	2.3yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Mogren's remuneration changed compared to Clinical Laserthermia Systems's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-kr80m
Sep 30 2023	n/a	n/a	-kr63m
Jun 30 2023	n/a	n/a	-kr77m
Mar 31 2023	n/a	n/a	-kr78m
Dec 31 2022	kr1m	kr1m	-kr71m
Sep 30 2022	n/a	n/a	-kr81m
Jun 30 2022	n/a	n/a	-kr63m
Mar 31 2022	n/a	n/a	-kr68m
Dec 31 2021	kr2m	kr1m	-kr64m

Compensation vs Market: Dan's total compensation ($USD126.13K) is below average for companies of similar size in the German market ($USD2.47M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan Mogren (59 yo)

3.3yrs

Tenure

kr1,373,158

Compensation

Mr. Dan Johansson Mogren was Acting Chief Executive Officer at Clinical Laserthermia Systems AB (publ) since December 01, 2020 until May 2022 and is Chief Executive Officer May 2022 and served as its Chief...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dan Mogren	Chief Executive Officer	3.3yrs	kr1.37m	0.0080% SEK 198.4k
Lars-Erik Eriksson	Co-Founder & Director	no data	kr1.65m	no data
Hakan Rosqvist	Interim Chief Financial Officer	less than a year	no data	no data
Jimmy Johansson	Executive Vice President of Operations	less than a year	no data	no data
Cristina Pantaleone	Chief Technical Officer	2.3yrs	no data	no data
Liselotte Nilsson	Vice President of Marketing	3.3yrs	no data	0.0013% SEK 31.3k
Karin Peterson	Chief Product Officer	no data	no data	no data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: LS6's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars-Erik Eriksson	Co-Founder & Director	18.3yrs	kr1.65m	no data
Stephan Dymling	Director	2.3yrs	kr75.00k	0.0099% SEK 244.0k
Hans von Celsing	Independent Chairman of the Board	11.3yrs	kr250.00k	0.085% SEK 2.1m
Gunilla Savring	Independent Director	4.3yrs	kr142.50k	no data
Rolf Kiessling	Member of Clinical Advisory Board	2.8yrs	kr80.00k	no data
Karl-Göran Tranberg	Member of Clinical Advisory Board	2.8yrs	kr80.00k	0.14% SEK 3.4m
Paolo Raffaelli	Independent Director	3.3yrs	kr62.50k	0.0013% SEK 31.3k
Marika Crohns	Independent Director & Member of Clinical Advisory Board	4.3yrs	kr142.50k	0.00036% SEK 8.9k
Sandy Brandmeier	Independent Director	3.3yrs	no data	no data

3.3yrs

Average Tenure

68yo

Average Age

Experienced Board: LS6's board of directors are considered experienced (3.3 years average tenure).

Clinical Laserthermia Systems Management

Management criteria checks 4/4

Key information

Recent management updates

Clinical Laserthermia Systems AB (publ) Announces CFO Changes

Clinical Laserthermia Systems AB (publ) Announces Members of the Nomination Committee Appointments

Clinical Laserthermia Systems AB (publ) Announces Executive Changes

High number of new directors

Clinical Laserthermia Systems AB (publ) Announces Resignation of Rolf Ho Bornschein as CFO

Clinical Laserthermia Systems AB (publ), Annual General Meeting, Jun 29, 2023

Recent updates

Clinical Laserthermia Systems AB (Pub) Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy

Clinical Laserthermia Systems AB (publ) Announces CFO Changes

Clinical Laserthermia Systems AB (publ) Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.06 loss per share (vs kr0.85 loss in FY 2022)

Clinical Laserthermia Systems AB (publ) to Report Q2, 2024 Results on Aug 23, 2024

Clinical Laserthermia Systems AB (Publ) Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044

Clinical Laserthermia Systems AB (publ) Receives Market Approval for Its TRANBERG Portfolio by HSA in Singapore and Initiates the Process of Commercialization in the Region

Clinical Laserthermia Systems AB (publ) Announces Members of the Nomination Committee Appointments

Clinical Laserthermia Systems AB (publ) Announces Executive Changes

Clinical Laserthermia Systems AB (publ) Announces First Patient was Safely Treated with CLS TRANBERG® Thermal Therapy system for laser ablation of Prostate Cancer

High number of new directors

Third quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ) Announces Enrollment Completion of Initial Phase and Extension of Clinical Trial at Radboud University Medical Center

Clinical Laserthermia Systems AB (publ) Announces Resignation of Rolf Ho Bornschein as CFO

Second quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Clinical Laserthermia Systems AB Appoints Jimmy Johansson as Executive VP Operations

Full year 2022 earnings released: kr0.57 loss per share (vs kr1.11 loss in FY 2021)

Clinical Laserthermia Systems AB (Publ) Announces First Glioblastoma Patient Treated with the Mr-Guided Laser Interstitial Thermal Therapy (MRg LITT) in the Study At Skåne University Hospital

Third quarter 2022 earnings released

High number of new and inexperienced directors

BioStock Studio Announces FDA clearance

Clinical Laserthermia Systems Receives 510(K) Clearance for Its MR Guided Laser Ablation System in Neurosurgery and Initiates Commercialization

Second quarter 2022 earnings released

Clinical Laserthermia Systems AB (publ) Appoints Rolf Ho Bornschein as the New CFO, Effective October 1, 2022 Replacing Lars-Erik Eriksson

Clinical Laserthermia Systems AB (publ) to Report Fiscal Year 2022 Final Results on Feb 23, 2023

Clinical Laserthermia Systems AB (Publ) Appoints Dan J. Mogren as Permanent CEO

Clinical Laserthermia Systems AB's Subsidiary CLS Americas Announces First Patient Treated in Clinical Study Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-To-Intermediate Risk Prostate Cancer

Clinical Laserthermia Systems AB (publ) Releases Ce-Marked New Version of Thermoguide™ Workstation for Use Also with Mri Scanners from GE Healthcare

Clinical Laserthermia Systems AB (Publ) Announces CEO Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clinical Laserthermia Systems AB (publ) Announces CEO Changes

Clinical Laserthermia Systems AB (publ) Files 510 (K) Application with the U.S. Food and Drug Administration for the Second Generation of TRANBERG®

Clinical Laserthermia Systems AB (Publ) Again Releases Tranberg® Sterile Disposable Products on the European Market and Enters into an Agreement with Two Additional Suppliers of Sterilization Services

Third quarter 2021 earnings released

Clinical Laserthermia Systems AB (Publ) to Present TRANBERG® Laser Thermal Therapy System and Latest Enhancements at the 73rd Congress of the German Society for Urology Conference

Second quarter 2021 earnings released

Clinical Laserthermia Systems AB (publ) and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Clinical Laserthermia Systems AB (publ) and University Hospital Magdeburg Obtains the Go for the Investigator Initiated Trial on Focal Laser Ablation Treatment of Localized Prostate Cancer, with the TRANBERG

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.24 loss per share (vs kr1.25 loss in FY 2019)

New 90-day low: €0.39

New 90-day low: €0.42

New 90-day low: €0.45

New 90-day low: €0.59

Clinical Laserthermia Systems AB (Publ) and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

CLS Receives New CPT® Reimbursement Code Approval by American Medical Association for Ultrasound-Guided Focal Laser Ablation of Prostate Cancer

New 90-day low: €0.65

Clinical Laserthermia Systems AB (Publ) and University Hospital Magdeburg Launch Clinical Trial Regarding Focal Laser Ablation Treatment of Localized Prostate Cancer

First half earnings released

New 90-day high - €0.82

New 90-day high - €0.71

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age